These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1098 related articles for article (PubMed ID: 33162723)
1. Stability analysis in COVID-19 within-host model with immune response. Almocera AES; Quiroz G; Hernandez-Vargas EA Commun Nonlinear Sci Numer Simul; 2021 Apr; 95():105584. PubMed ID: 33162723 [TBL] [Abstract][Full Text] [Related]
2. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V Elife; 2020 May; 9():. PubMed ID: 32452762 [TBL] [Abstract][Full Text] [Related]
4. Global dynamics of SARS-CoV-2/cancer model with immune responses. Elaiw AM; Al Agha AD Appl Math Comput; 2021 Nov; 408():126364. PubMed ID: 34002102 [TBL] [Abstract][Full Text] [Related]
5. Global Dynamics of SARS-CoV-2 Infection with Antibody Response and the Impact of Impulsive Drug Therapy. Chatterjee AN; Basir FA; Biswas D; Abraha T Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366355 [TBL] [Abstract][Full Text] [Related]
9. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. Li K; Meyerholz DK; Bartlett JA; McCray PB mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553 [TBL] [Abstract][Full Text] [Related]
10. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus. Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775 [TBL] [Abstract][Full Text] [Related]
11. Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19. Cantwell AM; Singh H; Platt M; Yu Y; Lin YH; Ikeno Y; Hubbard G; Xiang Y; Gonzalez-Juarbe N; Dube PH J Virol; 2021 Sep; 95(20):e0101021. PubMed ID: 34319784 [TBL] [Abstract][Full Text] [Related]
12. A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV). Noor R Arch Microbiol; 2021 Jul; 203(5):1943-1951. PubMed ID: 33682075 [TBL] [Abstract][Full Text] [Related]
13. The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus. Wu Z; Harrich D; Li Z; Hu D; Li D Rev Med Virol; 2021 Mar; 31(2):e2171. PubMed ID: 33350025 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. Yasmin H; Saha S; Butt MT; Modi RK; George AJT; Kishore U Adv Exp Med Biol; 2021; 1313():99-134. PubMed ID: 34661893 [TBL] [Abstract][Full Text] [Related]
15. Within Host Dynamics of SARS-CoV-2 in Humans: Modeling Immune Responses and Antiviral Treatments. Ghosh I SN Comput Sci; 2021; 2(6):482. PubMed ID: 34661166 [TBL] [Abstract][Full Text] [Related]
16. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094 [TBL] [Abstract][Full Text] [Related]
17. Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic. Sansone NMS; Boschiero MN; Ortega MM; Ribeiro IA; Peixoto AO; Mendes RT; Marson FAL Lancet Reg Health Am; 2022 Apr; 8():100177. PubMed ID: 35018359 [TBL] [Abstract][Full Text] [Related]
18. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2. Yao Z; Zheng Z; Wu K; Junhua Z Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527 [TBL] [Abstract][Full Text] [Related]
19. The host immune response of a discharged COVID-19 patient with twice reemergence of SARS-CoV-2: a case report. Zao X; Zhou Y; Liang Y; Cao X; Chen H; Li X; Ye Y BMC Infect Dis; 2021 Sep; 21(1):991. PubMed ID: 34556058 [TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis - An updated review. Bhat EA; Khan J; Sajjad N; Ali A; Aldakeel FM; Mateen A; Alqahtani MS; Syed R Int Immunopharmacol; 2021 Jun; 95():107493. PubMed ID: 33721758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]